Provided by Tiger Fintech (Singapore) Pte. Ltd.

Revelation Biosciences, Inc.

2.97
+0.21287.71%
Volume:15.38K
Turnover:43.57K
Market Cap:2.69M
PE:-0.02
High:2.97
Open:2.70
Low:2.70
Close:2.76
Loading ...

Revelation Biosciences Inc - on Feb 19, Regained Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
25 Feb

Revelation Biosciences, Inc. Receives Continued Nasdaq Listing Approval

THOMSON REUTERS
·
24 Feb

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Business Wire
·
24 Feb

REVB Start 1B Trial and Announces Split

Zacks Small Cap Research
·
29 Jan

Revelation Biosciences announces 1-for-16 reverse stock split

TIPRANKS
·
24 Jan

BRIEF-Revelation Biosciences Announces 1-For-16 Reverse Stock Split

Reuters
·
24 Jan

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

THOMSON REUTERS
·
24 Jan

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Business Wire
·
24 Jan

Revelation Biosciences starts Phase 1b clinical study of Gemini in CKD

TIPRANKS
·
21 Jan

Revelation Biosciences: Top-Line Data Including Safety, Tolerability & Biomarkers of Target Activity Are Expected by Mid-Year

THOMSON REUTERS
·
21 Jan

Revelation Biosciences Starts Its Prime Phase 1B Clinical Study of Gemini in Ckd Patients

THOMSON REUTERS
·
21 Jan

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Business Wire
·
21 Jan

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Business Wire
·
13 Jan

BRIEF-Nasdaq Grants Revelation Biosciences Continued Listing

Reuters
·
06 Jan

Revelation Biosciences granted continued listing status on Nasdaq

TIPRANKS
·
06 Jan

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

THOMSON REUTERS
·
06 Jan